within Pharmacolibrary.Drugs.ATC.J;

model J05AP54
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.32,
    Cl             = 15.8 / 1000 / 60,
    adminDuration  = 600,
    adminMass      = 50 / 1000000,
    adminCount     = 1,
    Vd             = 0.68,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.007783333333333334,
    Tlag           = 9.96
  );

  annotation(Documentation(
    info ="<html><body><p>Elbasvir and grazoprevir is a fixed-dose combination of two direct-acting antiviral agents used for the treatment of chronic hepatitis C virus (HCV) infection. Elbasvir is an HCV NS5A inhibitor and grazoprevir is an HCV NS3/4A protease inhibitor. This combination is approved and in current clinical use for adults with genotype 1 or 4 HCV infection.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetics in healthy adult subjects after a single tablet containing elbasvir 50 mg and grazoprevir 100 mg administered orally.</p><h4>References</h4><ol><li><p>Sulejmani, N, et al., &amp; Gordon, SC (2016). Pharmacodynamics and pharmacokinetics of elbasvir and grazoprevir in the treatment of hepatitis C. <i>Expert opinion on drug metabolism &amp; toxicology</i> 12(3) 353–361. DOI:<a href=&quot;https://doi.org/10.1517/17425255.2016.1148685&quot;>10.1517/17425255.2016.1148685</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/26849059/&quot;>https://pubmed.ncbi.nlm.nih.gov/26849059</a></p></li><li><p>Landaverde, C, et al., &amp; Goldstein, JL (2016). Dual therapy of grazoprevir and elbasvir for the treatment of hepatitis C infection. <i>Expert review of gastroenterology &amp; hepatology</i> 10(4) 419–429. DOI:<a href=&quot;https://doi.org/10.1586/17474124.2016.1147346&quot;>10.1586/17474124.2016.1147346</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/26818134/&quot;>https://pubmed.ncbi.nlm.nih.gov/26818134</a></p></li><li><p>Feng, HP, et al., &amp; Yeh, WW (2018). Pharmacokinetic Interactions Between Elbasvir/Grazoprevir and Immunosuppressant Drugs in Healthy Volunteers. <i>Journal of clinical pharmacology</i> 58(5) 666–673. DOI:<a href=&quot;https://doi.org/10.1002/jcph.1052&quot;>10.1002/jcph.1052</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/29329497/&quot;>https://pubmed.ncbi.nlm.nih.gov/29329497</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end J05AP54;
